WT1 gene expression: Useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?

Peter Bader, Charlotte Niemeyer, Gerrit Weber, Tiziana Coliva, Vincenzo Rossi, Hermann Kreyenberg, Anja Gerecke, Andrea Biondi

Research output: Contribution to journalArticlepeer-review

Abstract

The WT1 gene is considered to be highly expressed in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia and chronic myeloid leukemia and is thought to play a key role in maintaining the viability of leukemia cells. However, little is known about the WT1 gene expression levels in pediatric patients with juvenile myelo-monocytic leukemia (JMML) and myelodysplastic syndromes (MDS). We studied WT1 expression in diagnostic bone marrow (BM) and peripheral blood (PB) samples of 90 patients with JMML, low grade MDS, advanced MDS and myelodysplasia-related AML in BM (n = 20) and PB (n = 18) samples of normal healthy volunteer donors.

Original languageEnglish
Pages (from-to)25-28
Number of pages4
JournalEuropean Journal of Haematology
Volume73
Issue number1
DOIs
Publication statusPublished - Jul 2004

Keywords

  • Childhood
  • Juvenile myelo-monocytic leukemia
  • Minimal residual disease
  • Myelodysplastic syndromes
  • WT1 gene expression

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'WT1 gene expression: Useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?'. Together they form a unique fingerprint.

Cite this